C12N 2760/18222
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18222 (New viral proteins or individual genes, new structural or functional aspects of) appears on 35 US grants and 83 published applications in this corpus.
Search patents in C12N- Granted patents
- 35
- Published applications
- 83
- Assignees
- 52
- Inventors
- 152
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 2 |
| 2007 | 0 | 3 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 2 | 2 |
| 2011 | 0 | 1 |
| 2012 | 1 | 1 |
| 2013 | 1 | 2 |
| 2014 | 1 | 0 |
| 2015 | 2 | 4 |
| 2016 | 1 | 3 |
| 2017 | 1 | 5 |
| 2018 | 3 | 1 |
| 2019 | 4 | 7 |
| 2020 | 2 | 1 |
| 2021 | 1 | 6 |
| 2022 | 4 | 5 |
| 2023 | 3 | 5 |
| 2024 | 3 | 7 |
| 2025 | 4 | 14 |
| 2026 | 2 | 13 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- CD8-specific antibody constructs and compositions thereof7 Jul 2026US 12,674,180 B2Sana Biotechnology, Inc.
- Paramyxovirus virus-like particles as protein delivery vehicles14 Apr 2026US 12,600,956 B2The Penn State Research Foundation
- Fusosome compositions and uses thereof5 Aug 2025US 12,378,578 B2Flagship Pioneering Innovations V, Inc.
- Vaccines against Nipah virus, and methods of using same15 Jul 2025US 12,357,683 B2The Wistar Institute of Anatomy and Biology
- Paramyxovirus virus-like particles as protein delivery vehicles1 Apr 2025US 12,264,338 B2The Penn State Research Foundation
- Universal protein g fusogens and adapter systems thereof and related lipid particles and uses24 Sep 2026US 2026/0286388 A1Sana Biotechnology, Inc.
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Engineered recombinant retroviruses10 Sep 2026US 2026/0265776 A1Kelonia Therapeutics, Inc.
- Cd8-specific antibody constructs and compositions thereof10 Sep 2026US 2026/0265780 A1Sana Biotechnology, Inc.
- Engineered nipah virus mrna vaccine20 Aug 2026US 2026/0240981 A1Vernagen, LLC
Most cited
By later US patents
- Henipavirus vaccine9US 11,524,066 B2CureVac AG · 2022
- Nipah virus envelope pseudotyped lentiviruses and methods of their use7US 10,064,958 B2The Regents of the University of California · 2018
- Nipah virus envelope glycoprotein pseudotyped lentivirus7US 11,608,509 B2Centre National de la Recherche Scientifique (CNRS) · 2023
- Paramyxovirus virus-like particles as protein delivery vehicles6US 10,316,295 B2The Penn State Research Foundation · 2019
- Nipah virus envelope pseudotyped lentiviruses and methods of their use6US 11,576,982 B2The Regents of the University of California · 2023